Why am I still sick?
Need copy here
Are you suffering from neurologic and/or psychiatric symptoms that haven’t responded to treatment?
You are not alone.
As many as 60% of patients worldwide with neurologic, psychiatric and behavioral disorders do not respond to standard treatments, such as psychotropic and anti-seizure medications.
These patients have often tried multiple medications and therapies with minimal or no improvement. In some cases, medications have made their symptoms worse.
Treatment resistance affects an estimated 30% of individuals with major depressive disorder.
Treatment resistance affects an estimated 30% of individuals with major depressive disorder.
patients tested
years of research and development
Harnessing the power of real-world data to improve patients’ lives.
We are intently focused on the discovery and development of next-generation technologies for the identification, diagnosis, and treatment of patients suffering from immune-mediated neuropsychiatric, cardiovascular, Long-COVID and neuro-degenerative disorders.
Our unique technology platform consists of three integrated components, which, when utilized together, lead to unprecedented discoveries. Moleculera’s platform includes: blood-based autoantibody testing panels, an expansive biorepository of phenotypically curated specimens, and a novel biomarker and targeted therapeutic identification program.
Blood Panel
Bioinformatics
Programs
Neuropsychiatric symptoms that may be caused by an autoimmune reaction
Transforming care with precision medicine.
At Moleculera Biosciences, a precision medicine company, we envision a world in which patients will be treated by targeting an identified, underlying root cause, rather than simply treating symptoms. We look beneath the surface of complex disorders to discover if there is an immune-mediated basis for chronic central nervous system (CNS) and cardiovascular disorders.
Once an immune-mediated root is identified, tailored treatments can dramatically improve a patient’s life – greatly reducing or eliminating symptoms that were once debilitating.
Improving patient care through precision testing.
The Autoimmune Brain Panel™ includes a series of five high-complexity blood tests that assists clinicians in determining whether a patient’s neuropsychiatric symptoms may be due to a treatable autoimmune dysfunction, rather than a primary neurologic or psychiatric illness. Once diagnosed and treated properly, patients often experience a complete resolution or dramatic reduction in symptoms.
Autoimmune
Brain Panel™
Autoimmune
Heart Panel™
Long-COVID
Panel™
Neuro-degenerative
Disorder Panel™
Empowering Science.
Multiple Translational Programs
Moleculera Biosciences is advancing multiple translational programs to address the unmet needs of patients suffering from chronic, immune-mediated neuropsychiatric, cardiovascular, Long-COVID, and neuro-degenerative disorders. The company has a robust pipeline of multiple autoantibody panels including: the Autoimmune Brain Panel™ (our signature program already in the market), the Autoimmune Heart Panel™, the Long-COVID Panel™, and the Neuro-degenerative Disorder Panel™.
Medical Resources For Healthcare Providers
We are committed to helping healthcare providers improve clinical outcomes for patients with treatment resistant neuropsychiatric symptoms.
Could your symptoms be due to an immune dysfunction?
Answer a few questions to find out if you might benefit from testing with the Autoimmune Brain Panel™.
IN THE NEWS
